Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Thermo Fisher, Veracyte, GenapSys, More

Thermo Fisher Scientific: Alan Sachs, Karen Nelson

Thermo Fisher Scientific has appointed its current CSO Alan Sachs to the newly established role of chief medical officer. Sachs, who has served as CSO since 2016, will be succeeded by Karen Nelson, who previously served as president of the J. Craig Venter Institute. Both will join the company leadership team in August 2021.

In his new role, Sachs will help identify and promote the adoption of new technologies that benefit customers in the clinical space, and he will lead the company's medical affairs program, Thermo Fisher said. Nelson, who joined Thermo Fisher on July 6, currently serves as editor-in-chief of the journals Microbial Ecology and the newly formed PNAS Nexus. She is also an elected member of the National Academy of Sciences and a fellow of the American Academy of Microbiology.

Veracyte: Rob Brainin, Bill Zondler

Veracyte has appointed Rob Brainin as executive vice president and chief business officer, and Bill Zondler as senior vice president and chief information officer.

Brainin most recently served as CEO of Genuity Science (formerly known as WuXi NextCode). Prior to that, he was vice president and general manager of life sciences and applied genomics at Illumina. He also previously served as vice president and general manager of enterprise genomics solutions at Thermo Fisher Scientific, after having held a number of positions at Life Technologies and its predecessor, Invitrogen. Earlier in his career, Brainin was a management consultant at McKinsey & Co. and has served as an adjunct professor at the University of San Diego School of Law. He is a member of the board of directors of Champions Oncology and the Children's Tumor Foundation. He holds a bachelor's degree in economics from Emory University and a J.D. degree from Harvard Law School.

Zondler joins Veracyte from Biotheranostics, part of Hologic, where he served as CIO. Prior to that, he was the full-time consulting CIO at Axovant Sciences, a New York-based pharmaceutical firm. He has also previously served as CIO at Millennium Health; vice president of information services and CIO at Prometheus Laboratories; and vice president of information technologies and facilities at Sanford Burnham Prebys Medical Discovery Institute in San Diego.

GenapSys: Dana Moss, Aric Ledford, Richard Lyon

GenapSys has added Dana Moss as general counsel and corporate secretary, Aric Ledford as VP of IP and regulatory and assistant general counsel, and Richard Lyon as VP of operations and product realization.

Moss comes to GenapSys from the law firm Cooley, where she was a partner working in commercial litigation. She holds a J.D. from the University of Maryland.

Ledford was previously head of IP at Fluidigm. He holds a J.D. from Santa Clara University and a master's degree in molecular biology from East Carolina University.

Lyon has 38 years of experience in semiconductor circuit design. He comes to GenapSys from Fujifilm Dimatix, where he was senior director of technical operations, and has worked at Fairchild Semiconductor, American Microsystems, Xicor, Applied Materials, Infineon, and Ion Torrent — where he led manufacturing, operations, and technical program management.

For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.